CHB Investment Group LLC Buys New Shares in Axon Enterprise, Inc. (NASDAQ:AXON)

CHB Investment Group LLC purchased a new stake in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 9,075 shares of the biotechnology company's stock, valued at approximately $3,626,000. Axon Enterprise makes up about 1.9% of CHB Investment Group LLC's investment portfolio, making the stock its 5th largest holding.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in Axon Enterprise by 2.7% during the first quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company's stock worth $2,547,878,000 after purchasing an additional 212,401 shares during the last quarter. Motley Fool Asset Management LLC boosted its holdings in Axon Enterprise by 238.7% in the 1st quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company's stock worth $153,981,000 after buying an additional 346,838 shares during the period. 1832 Asset Management L.P. boosted its holdings in Axon Enterprise by 44.0% in the 2nd quarter. 1832 Asset Management L.P. now owns 375,700 shares of the biotechnology company's stock worth $110,546,000 after buying an additional 114,800 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in Axon Enterprise by 13.9% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 368,732 shares of the biotechnology company's stock worth $108,496,000 after purchasing an additional 45,049 shares in the last quarter. Finally, Thrivent Financial for Lutherans lifted its stake in Axon Enterprise by 1.6% in the 2nd quarter. Thrivent Financial for Lutherans now owns 270,430 shares of the biotechnology company's stock worth $79,571,000 after purchasing an additional 4,365 shares in the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on AXON. Barclays increased their target price on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 7th. Robert W. Baird raised their price objective on shares of Axon Enterprise from $360.00 to $400.00 and gave the company an "outperform" rating in a research report on Tuesday, September 10th. JMP Securities lifted their target price on shares of Axon Enterprise from $375.00 to $430.00 and gave the stock an "outperform" rating in a research report on Thursday, September 12th. Craig Hallum lifted their target price on shares of Axon Enterprise from $370.00 to $376.00 and gave the stock a "buy" rating in a research report on Wednesday, August 7th. Finally, Bank of America began coverage on shares of Axon Enterprise in a report on Wednesday, July 17th. They issued a "buy" rating and a $380.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $365.38.

Axon Enterprise Trading Up 0.1 %

NASDAQ:AXON opened at $434.48 on Friday. Axon Enterprise, Inc. has a one year low of $199.29 and a one year high of $440.89. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. The company's 50-day simple moving average is $387.25 and its 200 day simple moving average is $330.76. The firm has a market capitalization of $32.83 billion, a P/E ratio of 114.64, a PEG ratio of 11.74 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.18. The business had revenue of $504.00 million during the quarter, compared to analysts' expectations of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The business's revenue for the quarter was up 34.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.80 earnings per share. As a group, analysts forecast that Axon Enterprise, Inc. will post 1.79 EPS for the current fiscal year.

Insider Activity

In related news, President Joshua Isner sold 25,811 shares of the business's stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $359.84, for a total transaction of $9,287,830.24. Following the completion of the sale, the president now directly owns 228,166 shares in the company, valued at approximately $82,103,253.44. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Axon Enterprise news, Director Jeri Williams sold 110 shares of the company's stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $400.00, for a total value of $44,000.00. Following the completion of the transaction, the director now directly owns 1,934 shares in the company, valued at $773,600. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, President Joshua Isner sold 25,811 shares of the company's stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $359.84, for a total transaction of $9,287,830.24. Following the transaction, the president now owns 228,166 shares of the company's stock, valued at approximately $82,103,253.44. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 371,172 shares of company stock valued at $137,000,162 over the last three months. Insiders own 5.70% of the company's stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.